Japan is considering a new approach to its “special” market expansion re-pricing that would exclude drug sales tied to private…
HOME > BUSINESS
BUSINESS
- DSP to Reconstruct its Business Strategy Due to Acquisition of BBI and Slow Business in North America
May 14, 2012
- The Growing Presence of Foreign-Affiliates (2)
May 14, 2012
- Struggles in US Operations Lead to 5.3% Fall in Sales, Strategic Products at Home Post 25% Rise: Shionogi
May 11, 2012
- “Figures to Look Forward to in 2013-2014” in Firm US Operations: President Teshirogi of Shionogi
May 11, 2012
- Seikagaku Licenses Domestic Marketing Rights to Kaken Pharmaceutical for Hernia Treatment SI-6603
May 11, 2012
- Executive Officer Terukazu Kato to Become New President: Tsumura
May 11, 2012
- Ono Aims to Decrease Sales Ratio of Long-Listed Drugs to 50% Level within FY2012: President Sagara
May 11, 2012
- Senior Executive Director Mitsutomo Miyashita to Be Appointed as New President: Kyorin
May 11, 2012
- Company Results for March Show Slight Fall in Drug Sales on Impact of Generics: MTPC
May 10, 2012
- Tenelia Planned to “Overwhelm Market with Power” in Alliance with Daiichi Sankyo: MTPC
May 10, 2012
- Japan Blood Products Organization to Begin Operations in October: JRCS, MTPC
May 10, 2012
- Once-Monthly Abilify Significantly Extends Time to Relapse in Adult Schizophrenia Patients: Otsuka
May 10, 2012
- Shionogi’s US Subsidiary Submits NDA for VVA Treatment Ospemifene in the US
May 10, 2012
- Bayer, Santen to Copromote VEGF Trap-Eye Injection
May 10, 2012
- Daiichi Sankyo Ties Up with Coherus BioSciences to Embark on Biosimilars Business
May 9, 2012
- Sanofi-aventis Initiates PIII Trial for Hydroxychloroquine for SLE, CLE
May 9, 2012
- Kyowa Medex Launches Companion Diagnostics of Poteligeo
May 9, 2012
- VIVUS Receives Approval for ED Treatment in the US: MTPC
May 9, 2012
- All-Case Surveillance Lifted for Remicade for Psoriasis: MTPC
May 9, 2012
- Roche to Discontinue Development of JT’s Dyslipidemia Treatment Dalcetrapib
May 9, 2012
ページ
Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…